Skip to main content
AGIO
NASDAQ Life Sciences

Agios Q3 Revenue Reaches $55.4M as Sickle Cell PDUFA Slips to February 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$31.9
Mkt Cap
$1.873B
52W Low
$22.24
52W High
$46
52W Position info
43% above low
Off High info
31% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

AGIO sits 43% above its 52-week low of $22.24.

Summary

Third-quarter product revenue at Agios reached $55.4 million, more than four times last year, while the FDA pushed the mitapivat sickle cell decision to February 1, 2027 after requesting REMS information. Cash of $907.0 million funds the launches, with non-GAAP profitability targeted for 2028.


Key Events · Earnings and Guidance · AGIO

  • Q3 Product Revenue Quadruples

    Worldwide mitapivat net revenue was $55.4 million versus $12.9 million a year earlier, split $48.7 million U.S. and $6.6 million ex-U.S.; U.S. revenue rose 20% sequentially on the AQVESME thalassemia launch.

  • Sickle Cell PDUFA Delayed to February 2027

    The FDA moved the mitapivat sickle cell sNDA goal date from November 1, 2026 to February 1, 2027 after requesting information on whether a REMS is needed and classifying the response as a major amendment; labeling discussions continue.

  • Loss Narrows on Cost Cuts

    Net loss was $65.0 million, or $1.09 per share, versus $103.4 million a year ago; R&D expense fell to $73.5 million from $86.8 million as headcount was cut by over 100 roles, a more than 35% reduction versus 2025.

  • Cash Funds Launches Through 2028 Target

    Cash, cash equivalents and marketable securities totaled $907.0 million at September 30, 2026, down from $1.2 billion at December 31, 2025, which management says funds both commercial launches and the pipeline with non-GAAP profitability targeted for 2028.


Analysis · AGIO · Life Sciences

The bull case rests on product revenue more than quadrupling to $55.4 million, with the company saying it has already topped its entire 2025 total in nine months. Against that, the sickle cell launch — mitapivat's largest addressable market — is now three months later than planned, after the FDA asked for more information on whether a REMS is needed and treated the reply as a major amendment. A $907.0 million balance sheet still funds both launches without raising money, and management is pointing to non-GAAP profitability in 2028. Helped by R&D cuts of more than 100 roles, the quarter's loss narrowed to $65.0 million from $103.4 million a year ago.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AGIO was trading at $31.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $22.24 to $46.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AGIO - Latest Insights

AGIO
Nov 05, 2026, 9:38 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.75
Real-time Price: $29.68 info
Change: +$0.930 (+3%) info
Market Cap: $1.775B info
AGIO
Nov 05, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $31.90
Real-time Price: $29.68 info
Change: -$2.22 (-7%) info
Market Cap: $1.775B info
AGIO
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $37.25
Real-time Price: $29.68 info
Change: -$7.57 (-20%) info
Market Cap: $1.775B info
AGIO
Jul 30, 2026, 9:56 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.52
Real-time Price: $29.68 info
Change: -$1.84 (-6%) info
Market Cap: $1.775B info
AGIO
Jul 30, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.25
Real-time Price: $29.68 info
Change: -$6.57 (-18%) info
Market Cap: $1.775B info